Inclusion MALT Dysbiosis Microbiote Bactéries Biomarker COLON-CANCER Résistance Patients experience Heart disease risk factors Anti-TNF Inflammatory bowel disease Colon Disease Progression Venous thromboembolism Effectiveness Fecal microbiota Acceptability Resistance Cell adhesion Eradication 18 FDG-PET/CT Contraindication Clinical guidelines Helicobacter pylori Immune cells Inhibitor Screening Upper gastrointestinal tract MARKER Drug Intestinal crypts MORTALITY Anti-TNF agents RISK IL12 Bacteria Original Article Clinical Over 80s Consensus Alkylating agents Gene methylation Algorithm Kidney diseases Crohn's disease Rituximab Primary sclerosing cholangitis Stricture Methylation Eligibility Endoscopic treatment Tailored therapy PCR Small molecules Dysbiose Epigenetics IBD IL23 Maintenance therapy Cancer DNA METHYLATION Neoadjuvant chemotherapy Tuberculosis Safety Colonic epithelial primary cells MICROBIOTA Gene expression Monitoring Disease progression Disability Crohn’s disease Vedolizumab Gènes Surgery Colon cancer Ulcerative colitis Cost effectiveness Thérapie ciblée DNA methylation HIV Microbiota Epigénétiques Inflammatory Bowel Diseases Rituximab plus chlorambucil Patient-reported outcome T1118 translocation Parvimonas micra Survival Therapeutics Biologics Méthylation Colorectal cancer CARCINOGENESIS Clinical trial Immunosuppressant Genes Inflammatory bowel diseases Ustekinumab Colorectal cancer Colibactin and lipids Colectomy